CD 19‐ CAR engineered NK ‐92 cells are sufficient to overcome NK cell resistance in B‐cell malignancies-Reference-Cited by-同舟云学术

CD 19‐ CAR engineered NK ‐92 cells are sufficient to overcome NK cell resistance in B‐cell malignancies

Published:2016-03-23 Issue:7 Volume:20 Page:1287-1294
ISSN:1582-1838
Container-title:Journal of Cellular and Molecular Medicine
language:en
Short-container-title:J. Cell. Mol. Med.

Author:

Romanski Annette¹²,Uherek Christoph³,Bug Gesine¹,Seifried Erhard²,Klingemann Hans⁴,Wels Winfried S.³,Ottmann Oliver G.¹,Tonn Torsten²⁵

Affiliation:

1. Department of Hematology J.W. Goethe University Frankfurt/Main Frankfurt Germany

2. Institute for Transfusion Medicine and Immunohematology J.W. Goethe University Frankfurt/Main Red Cross Blood Donor Service Baden‐Württemberg‐Hessen Dresden Germany

3. Georg‐Speyer‐Haus Institute for Tumor Biology and Experimental Therapy Frankfurt Germany

4. Nantkwest Inc & Tufts University Medical School Boston MA USA

5. Institute for Transfusion Medicine Dresden German Red Cross Blood Donation Service North/East Medical Faculty Carl Gustav Carus TU Dresden Dresden Germany

Funder

José Carreras Leukämie-Stiftung

Publisher

Wiley

Subject

Cell Biology,Molecular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jcmm.12810

Reference58 articles.

1. Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity

2. NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G

3. Human NKG2D-ligands: cell biology strategies to ensure immune recognition